Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Radical Chemistry and Cytotoxicity of Bioreductive 3-Substituted Quinoxaline Di-N-Oxides.

Anderson RF, Yadav P, Shinde SS, Hong CR, Pullen SM, Reynisson J, Wilson WR, Hay MP.

Chem Res Toxicol. 2016 Aug 15;29(8):1310-24. doi: 10.1021/acs.chemrestox.6b00133. Epub 2016 Jul 29.

PMID:
27380897
2.

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.

Abbattista MR, Jamieson SM, Gu Y, Nickel JE, Pullen SM, Patterson AV, Wilson WR, Guise CP.

Cancer Biol Ther. 2015;16(4):610-22. doi: 10.1080/15384047.2015.1017171. Epub 2015 Apr 14.

3.

Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.

Hunter FW, Hsu HL, Su J, Pullen SM, Wilson WR, Wang J.

Mol Cancer Ther. 2014 Nov;13(11):2501-14. doi: 10.1158/1535-7163.MCT-14-0476. Epub 2014 Sep 5.

4.

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.

Jamieson SM, Gu Y, Manesh DM, El-Hoss J, Jing D, Mackenzie KL, Guise CP, Foehrenbacher A, Pullen SM, Benito J, Smaill JB, Patterson AV, Mulaw MA, Konopleva M, Bohlander SK, Lock RB, Wilson WR.

Biochem Pharmacol. 2014 Mar 1;88(1):36-45. doi: 10.1016/j.bcp.2013.12.019. Epub 2014 Jan 13.

PMID:
24434189
5.

DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.

Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR.

Cancer Res. 2009 May 1;69(9):3884-91. doi: 10.1158/0008-5472.CAN-08-4023. Epub 2009 Apr 14.

6.

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, Yang S, Denny WA, Wilson WR.

Clin Cancer Res. 2007 Jul 1;13(13):3922-32.

7.

Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.

Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV.

Radiat Res. 2007 Jun;167(6):625-36.

PMID:
17523848
8.

Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.

Atwell GJ, Yang S, Pruijn FB, Pullen SM, Hogg A, Patterson AV, Wilson WR, Denny WA.

J Med Chem. 2007 Mar 22;50(6):1197-212. Epub 2007 Feb 28.

PMID:
17326614
9.

Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.

Helsby NA, Atwell GJ, Yang S, Palmer BD, Anderson RF, Pullen SM, Ferry DM, Hogg A, Wilson WR, Denny WA.

J Med Chem. 2004 Jun 3;47(12):3295-307.

PMID:
15163209
10.

2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.

Helsby NA, Ferry DM, Patterson AV, Pullen SM, Wilson WR.

Br J Cancer. 2004 Mar 8;90(5):1084-92.

11.

In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors.

Wilson WR, Pullen SM, Hogg A, Hobbs SM, Pruijn FB, Hicks KO.

Methods Mol Med. 2004;90:403-31. No abstract available.

PMID:
14657576
13.

Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores.

Tercel M, Stribbling SM, Sheppard H, Siim BG, Wu K, Pullen SM, Botting KJ, Wilson WR, Denny WA.

J Med Chem. 2003 May 22;46(11):2132-51.

PMID:
12747786
14.

Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.

Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA.

Cancer Res. 2002 Mar 1;62(5):1425-32.

15.

Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism.

Siim BG, Hicks KO, Pullen SM, van Zijl PL, Denny WA, Wilson WR.

Biochem Pharmacol. 2000 Oct 1;60(7):969-78.

PMID:
10974206
16.
17.
18.

Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.

Wilson WR, Denny WA, Pullen SM, Thompson KM, Li AE, Patterson LH, Lee HH.

Br J Cancer Suppl. 1996 Jul;27:S43-7.

19.
20.

Acquisition of prototype-based information about social groups in adulthood.

Hess TM, Pullen SM, McGee KA.

Psychol Aging. 1996 Mar;11(1):179-90.

PMID:
8726383
21.

Adult age differences in impression change processes.

Hess TM, Pullen SM.

Psychol Aging. 1994 Jun;9(2):237-50.

PMID:
8054172
22.

Nitrobenzyl mustard quaternary salts: a new class of hypoxia-selective cytotoxins capable of releasing diffusible cytotoxins on bioreduction.

Denny WA, Wilson WR, Tercel M, Van Zijl P, Pullen SM.

Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):317-21.

PMID:
8195026

Supplemental Content

Loading ...
Support Center